Want to see PMVP full AI Analyst Report?
Total Valuation
PMV Pharmaceuticals has a market cap or net worth of $65.06M. The enterprise value is $19.83M.
Market Cap$65.06M
Enterprise Value$19.83M
Share Statistics
PMV Pharmaceuticals has 53,331,764 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding53,331,764
Owned by Insiders12.70%
Owned by Institutions49.49%
Financial Efficiency
PMV Pharmaceuticals’s return on equity (ROE) is -0.74 and return on invested capital (ROIC) is -79.45%.
Return on Equity (ROE)-0.74
Return on Assets (ROA)-0.67
Return on Invested Capital (ROIC)-79.45%
Return on Capital Employed (ROCE)-0.82
Revenue Per Employee0.00
Profits Per Employee-1.65M
Employee Count47
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of PMV Pharmaceuticals is ―. PMV Pharmaceuticals’s PEG ratio is -0.03.
PE Ratio―
PS Ratio0.00
PB Ratio0.63
Price to Fair Value0.63
Price to FCF-0.89
Price to Operating Cash Flow-0.87
PEG Ratio-0.03
Income Statement
In the last 12 months, PMV Pharmaceuticals had revenue of 0.00 and earned -77.74M in profits. Earnings per share was -1.48.
Revenue0.00
Gross Profit0.00
Operating Income-86.21M
Pretax Income-79.91M
Net Income-77.74M
EBITDA-79.78M
Earnings Per Share (EPS)-1.48
Cash Flow
In the last 12 months, operating cash flow was -74.99M and capital expenditures -25.00K, giving a free cash flow of -75.02M billion.
Operating Cash Flow-74.99M
Free Cash Flow-75.02M
Free Cash Flow per Share-1.41
Dividends & Yields
PMV Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.47
52-Week Price Change1.67%
50-Day Moving Average1.26
200-Day Moving Average1.30
Relative Strength Index (RSI)51.64
Average Volume (3m)350.98K
Important Dates
PMV Pharmaceuticals upcoming earnings date is Aug 6, 2026, Before Open (Confirmed).
Last Earnings DateMay 12, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
PMV Pharmaceuticals as a current ratio of 10.09, with Debt / Equity ratio of 0.33%
Current Ratio10.09
Quick Ratio10.09
Debt to Market Cap<0.01
Net Debt to EBITDA0.47
Interest Coverage Ratio0.00
Taxes
In the past 12 months, PMV Pharmaceuticals has paid -2.17M in taxes.
Income Tax-2.17M
Effective Tax Rate0.03
Enterprise Valuation
PMV Pharmaceuticals EV to EBITDA ratio is -0.36, with an EV/FCF ratio of -0.39.
EV to Sales0.00
EV to EBITDA-0.36
EV to Free Cash Flow-0.39
EV to Operating Cash Flow-0.39
Balance Sheet
PMV Pharmaceuticals has $93.55M in cash and marketable securities with $293.00K in debt, giving a net cash position of $93.26M billion.
Cash & Marketable Securities$93.55M
Total Debt$293.00K
Net Cash$93.26M
Net Cash Per Share$1.75
Tangible Book Value Per Share$1.99
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for PMV Pharmaceuticals is $4.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$4.50
Price Target Upside301.79% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast-26.14%